Early-phase clinical data show promising results, with objective response rates of up to 45% when combining the HIF-2α antagonist belzutifan with LDH-A inhibitors in glycolytic-high RCC subsets [139]. The gene discussed is EPAS1; the disease is renal cell carcinoma.